新聞報導於2個月前
根據最近的報導，Relay Therapeutics, Inc. (NASDAQ:RLAY)被評為最具潛力的便士股票之一，分析師預測其股票有可能上升561.48%。該公司專注於精準醫療，主要產品候選包括RLY-2608，用於轉移性乳腺癌的治療。Despite revenue fluctuation, the company ended the quarter with substantial cash reserves to support ongoing clinical trials, indicating a promising outlook.
小見聞來源: YAHOO